Eribulin Mesylate for the Treatment of Metastatic Breast Cancer
M.S. Biological Sciences
Jose V. Lopez
Metastasis, the spread of cancer cells to a certain region of the body at a distance from the original primary cancer site, is the primary cause of all cancer deaths. Metastatic breast cancer accounts for approximately 40,000 deaths annually in the U.S. An average of only 10% of all patients with advanced metastatic breast cancersurvive. Treatment for metastatic breast cancer is a lifelong process, which focuses on the control of the disease and the quality of life. Unfortunately, effective treatment for metastatic breast cancer (MBC) continues to be a major challenge.Eribulinmesylate is the firstmonotherapy drug proven to prolong the lives of heavily pretreated metastatic breast cancer patients. It has distinguished itself from other anticancer agents due to its novel mechanism of actionof binding to tubulin. As a result of the encouraging observations shown in MBC patients through clinical trials, there is strong support for continued development of eribulin mesylate as novel anticancer agents for human use to improve and potentially inhibit metastatic breast cancer. This capstone report highlights these latest treatments, future outlook in the context ofmetatstatic cancer.
Abelardo Vernaza. 2015. Eribulin Mesylate for the Treatment of Metastatic Breast Cancer. Capstone. Nova Southeastern University. Retrieved from NSUWorks, . (282)